Ptk6-flox Mouse

PTK6, also known as Breast tumor kinase (Brk), is an intracellular tyrosine kinase distantly related to SRC family kinases. It functions in cell-type and context-dependent processes governing normal differentiation. In tumors, overexpressed PTK6 acts as a mediator of cancer cell phenotypes such as increased proliferation, survival, and migration. It phosphorylates nuclear and cytoplasmic substrates including regulatory RNA-binding proteins, adaptor molecules, and STAT molecules, influencing key signaling pathways [4].

PTK6 is overexpressed in multiple cancers. In clear cell renal carcinoma (KIRC), its overexpression is linked to worse outcomes, higher immune infiltration, and correlates with neo-antigens and DNA ploidy changes, suggesting it as a biomarker for prognosis and treatment [1]. In triple-negative breast cancer, especially in the lymph node metastasis positive group, PTK6 expression is higher and associated with poor prognosis [2]. In uveal melanoma, PTK6 promotes tumorigenesis by inhibiting autophagy through binding to SOCS3 and regulating mTOR phosphorylation [3]. In prostate cancer, elevated PTK6 expression, its translocation from the nucleus to the cytoplasm and activation at the plasma membrane promote cancer progression by phosphorylating substrates like AKT, p130CAS, and FAK [5]. Vemurafenib can inhibit active PTK6 in PTEN-null prostate tumor cells [6]. In Her2(+) breast cancer, PTK6 inhibition promotes apoptosis of Lapatinib-resistant cells by inducing Bim [7]. In hepatocellular carcinoma, PTK6 promotes cell proliferation and invasion [8]. In colorectal cancer, PTK6 activates autophagy and inhibits apoptosis by driving HNRNPH1 phase separation [9].

In conclusion, PTK6 plays a significant role in promoting cancer cell growth, metastasis, and survival across various cancer types. Its overexpression and activation are associated with poor prognosis in multiple cancers. The study of PTK6 in these disease models helps in understanding cancer-related biological processes, providing potential targets for cancer therapies.